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The Role of Menin-MLL interaction in Dissociation between Cholestatic Liver Disease and
Cholangiocarcinoma

Laurent Ehrlich, Chad Hall, Tori Sheppard, Julie Venter, April O’Brien, Terry C. Lairmore,
Gianfranco Alpini, Shannon Glaser
Multiple Endocrine Neoplasia type I (MEN1) is a familial cancer syndrome of the
parathyroid glands, pituitary glands, and pancreatic islet cells. We have recently shown
that menin, the protein encoded by MEN1, acts as a tumor suppressor in
cholangiocarcinoma (CCA). However, recent evidence points to menin as a positive
regulator of hepatic fibrosis. Thus, we sought to compare and contrast the role of menin in
cholestatic fibrotic disease states against CCA. Methods: We treated bile-duct ligation
(BDL) and MDR2-/- cholestatic mouse models with a menin-MLL (MI-2-2, 20-40 mg/kg, I.P.)
or vehicle for 1 week before collecting liver samples. Immunohistochemistry was
performed to measure intrahepatic bile duct mass (CK-19 staining) and Sirius Red staining
to quantify collagen deposition. By real-time PCR, expression of menin and markers for
proliferation (Ki67) and fibrosis (TGFbeta1, FN1, alpha-SMA, Col1alpha1) was measured.
Next we sought to understand the effect of menin-MLL interaction on human CCA growth.
Mz-ChA-1 cells were treated with MI-2-2 (10 microM, 24 hours) and menin expression was
assessed with real-time PCR and flow cytometry. Markers of proliferation (Ki67) and
angiogenesis (VEGF-A/C, VEGFR-2/3, angiopoietins Angpt1/2, and Tie1/2) were
measured. Results: MI-2-2 treatment reduces biliary mass and collagen deposition via
CK19 and Sirius Red staining in both BDL and MDR2-/- mice. Expression of proliferative
and fibrotic markers decreased in pure cholangiocytes isolated from MI-2-2 treated livers
of these mice as well. However, Mz-ChA-1 cells treated with MI-2-2 in vitro increased
expression of proliferative and angiogenic markers. Conclusion: The role of menin-MLL
interaction is dependent on the disease state or model. While it drives proliferation and
fibrosis in fibrotic liver diseases, it inhibits human CCA initiation and progression.
Understanding how menin-MLL functions in various diseases states can help us understand
how cholestatic liver diseases progress to CCA.

